<?xml version='1.0' encoding='utf-8'?>
<document id="27550354"><sentence text="Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family." /><sentence text="Twenty-two currently marketed antituberculosis drugs were comprehensively evaluated for their inhibitory effect on organic anionic transporter (OAT)- and organic cation transporter (OCT)-mediated uptake using stably transfected HEK293 cells in vitro We observed moderate to strong inhibitory effects on OAT1- and OAT3-mediated para-aminohippurate (PAH) uptake and OCT1- and OCT2-mediated N-methyl-4-phenylpylidinium acetate (MPP+) uptake"><entity charOffset="388-423" id="DDI-PubMed.27550354.s2.e0" text="N-methyl-4-phenylpylidinium acetate" /><entity charOffset="425-429" id="DDI-PubMed.27550354.s2.e1" text="MPP+" /><pair ddi="false" e1="DDI-PubMed.27550354.s2.e0" e2="DDI-PubMed.27550354.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27550354.s2.e0" e2="DDI-PubMed.27550354.s2.e1" /></sentence><sentence text=" Ciprofloxacin, linezolid, para-aminosalicylic acid (PAS), and rifampin were observed to have strong inhibitory effects, with the concentrations for a 50% inhibitory effect (IC50s) being 35"><entity charOffset="1-14" id="DDI-PubMed.27550354.s3.e0" text="Ciprofloxacin" /><entity charOffset="16-25" id="DDI-PubMed.27550354.s3.e1" text="linezolid" /><entity charOffset="27-51" id="DDI-PubMed.27550354.s3.e2" text="para-aminosalicylic acid" /><entity charOffset="53-56" id="DDI-PubMed.27550354.s3.e3" text="PAS" /><entity charOffset="63-71" id="DDI-PubMed.27550354.s3.e4" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e0" e2="DDI-PubMed.27550354.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e0" e2="DDI-PubMed.27550354.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e0" e2="DDI-PubMed.27550354.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e0" e2="DDI-PubMed.27550354.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e0" e2="DDI-PubMed.27550354.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e1" e2="DDI-PubMed.27550354.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e1" e2="DDI-PubMed.27550354.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e1" e2="DDI-PubMed.27550354.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e1" e2="DDI-PubMed.27550354.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e2" e2="DDI-PubMed.27550354.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e2" e2="DDI-PubMed.27550354.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e2" e2="DDI-PubMed.27550354.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e3" e2="DDI-PubMed.27550354.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s3.e3" e2="DDI-PubMed.27550354.s3.e4" /></sentence><sentence text="1, 31" /><sentence text="1, 37" /><sentence text="6, and 48" /><sentence text="1 μM, respectively, for OAT1 and &gt;100, 21" /><sentence text="9, 24" /><sentence text="6, and 30" /><sentence text="2 μM, respectively, for OAT3" /><sentence text=" Similarly, pyrazinamide, rifabutin, and levofloxacin were observed to have inhibitory effects, with IC50 values being 36"><entity charOffset="12-24" id="DDI-PubMed.27550354.s11.e0" text="pyrazinamide" /><entity charOffset="26-35" id="DDI-PubMed.27550354.s11.e1" text="rifabutin" /><entity charOffset="41-53" id="DDI-PubMed.27550354.s11.e2" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.27550354.s11.e0" e2="DDI-PubMed.27550354.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27550354.s11.e0" e2="DDI-PubMed.27550354.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s11.e0" e2="DDI-PubMed.27550354.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s11.e1" e2="DDI-PubMed.27550354.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s11.e1" e2="DDI-PubMed.27550354.s11.e2" /></sentence><sentence text="5, 42" /><sentence text="7, and 30" /><sentence text="3 μM, respectively, for OCT1 and with the IC50 value for PAS being 94"><entity charOffset="57-68" id="DDI-PubMed.27550354.s14.e0" text="PAS" /></sentence><sentence text="2 μM for OCT2" /><sentence text=" In addition, we used zidovudine and metformin as clinically prescribed substrates of OATs and OCTs, respectively, and zidovudine and metformin uptake was also strongly inhibited by the antituberculosis drugs"><entity charOffset="22-32" id="DDI-PubMed.27550354.s16.e0" text="zidovudine" /><entity charOffset="37-46" id="DDI-PubMed.27550354.s16.e1" text="metformin" /><entity charOffset="119-129" id="DDI-PubMed.27550354.s16.e2" text="zidovudine" /><entity charOffset="134-143" id="DDI-PubMed.27550354.s16.e3" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e0" e2="DDI-PubMed.27550354.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e0" e2="DDI-PubMed.27550354.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e0" e2="DDI-PubMed.27550354.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e0" e2="DDI-PubMed.27550354.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e1" e2="DDI-PubMed.27550354.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e1" e2="DDI-PubMed.27550354.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e1" e2="DDI-PubMed.27550354.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e2" e2="DDI-PubMed.27550354.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27550354.s16.e2" e2="DDI-PubMed.27550354.s16.e3" /></sentence><sentence text=" Among the tested drugs, the highest drug-drug interaction (DDI) indexes were found for PAS, which were 9"><entity charOffset="88-96" id="DDI-PubMed.27550354.s17.e0" text="PAS" /></sentence><sentence text="3 to 13" /><sentence text="9 for OAT1 and 12" /><sentence text="0 to 17" /><sentence text="7 for OAT3, and linezolid, which were 1"><entity charOffset="16-25" id="DDI-PubMed.27550354.s21.e0" text="linezolid" /></sentence><sentence text="18 to 2" /><sentence text="15 for OAT1 and 1" /><sentence text="7 to 3" /><sentence text="01 for OAT3" /><sentence text=" Similarly, the DDI indexes of pyrazinamide and levofloxacin were 0"><entity charOffset="31-43" id="DDI-PubMed.27550354.s26.e0" text="pyrazinamide" /><entity charOffset="48-60" id="DDI-PubMed.27550354.s26.e1" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.27550354.s26.e0" e2="DDI-PubMed.27550354.s26.e0" /><pair ddi="false" e1="DDI-PubMed.27550354.s26.e0" e2="DDI-PubMed.27550354.s26.e1" /></sentence><sentence text="57 and 0" /><sentence text="30, respectively, for OCT1, and the DDI index of PAS was 3"><entity charOffset="49-60" id="DDI-PubMed.27550354.s28.e0" text="PAS" /></sentence><sentence text="8 for OCT2, suggesting a stronger possibility (DDI index value cutoff, &gt;0" /><sentence text="1) of in vivo DDIs" /><sentence text=" This is the first comprehensive report of the inhibitory potential of anti-TB drugs on OAT- and OCT-mediated uptake of prototype and clinically prescribed substrate drugs in vitro, providing an ability to predict DDIs between anti-TB drugs and other coprescribed drugs in clinical studies in vivo" /><sentence text="" /></document>